01-7262. Availability for Non-Exclusvie, Exclusive, or Partially Exclusvie Licensing of U.S. Patent Application Concerning Use of Antibodies to Sialidase as Anti-Infectious Agents and Anti-Inflammatory Agents  

  • Start Preamble

    AGENCY:

    U.S. Army Medical Research and Materiel Command, DoD.

    ACTION:

    Notice.

    SUMMARY:

    In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent No. 6,066,323 entitled “Use of Antibodies to Sialidase as Anti-infectious Agents and Anti-Inflammatory Agents” issued May 23, 2000. This patent application has been assigned to the United States Government as represented by the Secretary of the Army.

    ADDRESSES:

    Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702-5012

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664. Both telefax (301) 619-5034.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    Sialic acids have the ability to prevent hyposialylation of cells as competitive inhibitors of endogenous sialidse. It is now also possible to develop antibodies to mammalian sialidase that significantly reduce influx of neutrophils into inflammatory sites.

    Start Signature

    Gregory D. Showalter,

    Army Federal Register Liaison Officer.

    End Signature End Supplemental Information

    [FR Doc. 01-7262 Filed 3-22-01; 8:45 am]

    BILLING CODE 3770-08-M

Document Information

Published:
03/23/2001
Department:
Army Department
Entry Type:
Notice
Action:
Notice.
Document Number:
01-7262
Pages:
16188-16188 (1 pages)
PDF File:
01-7262.pdf